Vertex Pharmaceuticals Stock Current Ratio
| VRTX Stock | MXN 9,266 148.99 1.63% |
Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.
Vertex |
Vertex Pharmaceuticals Company Current Ratio Analysis
Vertex Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Vertex Pharmaceuticals Current Ratio | 4.61 X |
Most of Vertex Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Vertex Pharmaceuticals has a Current Ratio of 4.61 times. This is 58.42% higher than that of the Healthcare sector and 34.14% lower than that of the Biotechnology industry. The current ratio for all Mexico stocks is 113.43% lower than that of the firm.
Vertex Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vertex Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics of similar companies.Vertex Pharmaceuticals is currently under evaluation in current ratio category among its peers.
Vertex Fundamentals
| Return On Equity | 0.28 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.37 % | |||
| Operating Margin | 0.49 % | |||
| Current Valuation | 1.41 T | |||
| Shares Outstanding | 257.09 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 96.96 % | |||
| Price To Earning | 17.50 X | |||
| Price To Book | 6.07 X | |||
| Price To Sales | 180.70 X | |||
| Revenue | 8.93 B | |||
| Gross Profit | 7.55 B | |||
| EBITDA | 4.29 B | |||
| Net Income | 3.32 B | |||
| Cash And Equivalents | 6.71 B | |||
| Cash Per Share | 25.86 X | |||
| Total Debt | 893.85 M | |||
| Debt To Equity | 0.1 % | |||
| Current Ratio | 4.61 X | |||
| Book Value Per Share | 54.13 X | |||
| Cash Flow From Operations | 2.64 B | |||
| Earnings Per Share | 238.31 X | |||
| Price To Earnings To Growth | 0.41 X | |||
| Number Of Employees | 4.8 K | |||
| Beta | 0.46 | |||
| Market Capitalization | 1.46 T | |||
| Total Asset | 18.15 B | |||
| Net Asset | 18.15 B |
About Vertex Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.